Navigation Links
Lumenis Sues Alma Lasers and its 4 founders for 200 Million Shekels

Claims that Alma founders, former Lumenis employees, misappropriated core

technology from Lumenis

YOKNEAM, Israel, March 26 /PRNewswire/ -- Lumenis Ltd. today filed a complaint in the Tel Aviv District Court in Israel against Alma Lasers Ltd. and its four founders, Ziv Karni, Yoav Avni, Nadav Bayer, and Ivgeni Kodritzki, all former employees of Lumenis, claiming misappropriation of Lumenis trade secrets and technology and for the use of such technology in Alma's primary Harmony products, which are sold worldwide. Lumenis has requested relief from the court in the form of an injunction against the use of such core technology by Alma in its products and for monetary damages in the amount of 200 million shekels based on the profits earned by Alma and its founders from the utilization of such Lumenis technology. Lumenis will also be filing a similar action against Alma Inc., the US subsidiary and distribution arm of Alma, in the Federal Court in the US.

The complaint alleges that certain core components of Alma's Harmony products are virtually identical to Lumenis components that were developed around the time the Alma founders departed from Lumenis. The complaint further alleges that at the time the four Alma founders left Lumenis to establish Alma, they were each involved in the development of Lumenis technology and products -- Ziv Karni was the head of Lumenis' R&D; Yoav Avni was employed as a mechanical engineer; Nadav Bayer was the manager of the electronics department, and Ivgeni Kodritzki worked as an electric and electronic engineer.

The claim further alleges that Alma has earned significant revenues from the sales of Harmony products -- profits that were unjustly earned as a result of the use of Lumenis technology. In addition, Alma's founders were recently paid substantial amounts by TA Associates as part of an investment agreement in Alma, profits which resulted from value created by Lumenis technology.

In June 2007, Lumenis filed an action against Alma for patent infringement in the US District Court in Chicago, Illinois claiming that Alma infringed seven of Lumenis' patents in the design of the Harmony product. This new action alleges that Alma went even further than mere patent infringement -- it alleges outright misappropriation of Lumenis technology that was developed by Lumenis over a long period of time and at Lumenis' great expense.

Dov Ofer, Lumenis' CEO stated that, "Lumenis has an extensive and valuable portfolio of technology, and the Company has undertaken a policy to enforce its intellectual property rights vigorously in what has become a highly competitive industry and business environment."

About Lumenis Ltd.

Lumenis is Israel's largest medical device company with more than 1,000 employees worldwide. The Company invests heavily in R&D and holds a leading position in the markets in which it serves. Lumenis has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over 100 countries, and an installed base of over 70,000 systems. In December 2006, a group led by a private equity consortium Viola Partners and Ofer Hi-Tech Group invested approximately $150 million in the Company.


Michelle Maydan

Director of Corporate Communications,



Lumenis(R) is a registered trademark of Lumenis Ltd.

SOURCE Lumenis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lumenis(R) Introduces the Newest Innovations in Fractional CO2 Laser Skin Therapy
2. Lumenis Ltd. Announces Senior Leadership Appointments Strengthening the Companys Strategic Businesses
3. Alma Lasers Answers Lumenis Complaint
4. Lumenis(R) Seeks Shareholder Approval of Proposed Class Action Settlement
5. Alma Lasers Announces Proposed Initial Public Offering
6. Alma(TM) Lasers to Debut Five New Products at the 66th Annual Meeting of the American Academy of Dermatology
7. FalconStor Software Inc. Founders Make Multi-Million Dollar Donation to North Shore-LIJ Health System for Asian Community Health Center in Flushing
8. Healthy Coffee USA Launches Founders Club
9. Wendell Tyler, of San Francisco 49ers Super Bowl XIX Fame, Joins Healthy Coffee USAs Founders Club
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. AUDIO from Medialink and Pfizer: Number of Uninsured Americans Grows to 47 Million
Post Your Comments:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: